Co-Authors
This is a "connection" page, showing publications co-authored by FAYE M JOHNSON and DAVID SANGHYUN HONG.
Connection Strength
0.379
-
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs. 2018 06; 36(3):416-423.
Score: 0.152
-
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. J Clin Oncol. 2016 05 20; 34(15):1764-71.
Score: 0.137
-
Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer. 2010 Mar 15; 116(6):1582-91.
Score: 0.090